行情

AFMD

AFMD

Affimed
NASDAQ

实时行情|Nasdaq Last Sale

2.700
-0.040
-1.46%
盘后: 2.700 0 0.00% 16:00 02/21 EST
开盘
2.750
昨收
2.740
最高
2.760
最低
2.620
成交量
42.33万
成交额
--
52周最高
4.680
52周最低
2.180
市值
1.73亿
市盈率(TTM)
-14.6580
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测AFMD价格均价为6.99,最高价位9.98,最低价为4.990。

EPS

AFMD 新闻

更多
  • Affimed to Present at the SVB Leerink 9th Annual Global Healthcare Conference
  • GlobeNewswire · 3天前
  • Affimed Mourns Passing of Chief Financial Officer Dr. Florian Fischer
  • GlobeNewswire · 02/03 12:30
  • Affimed: An Impressive Platform And An Enticing Valuation
  • Seeking Alpha - Article · 01/28 00:15
  • Affimed Announces Appointment of Andreas Harstrick, M.D., as Chief Medical Officer
  • GlobeNewswire · 01/10 11:30

所属板块

生物技术和医学研究
+0.37%
制药与医学研究
+0.54%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

AFMD 简况

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.
展开

微牛提供Affimed NV(NASDAQ-AFMD)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的AFMD股票新闻,以帮助您做出投资决策。